Nektar Therapeutics (NKTR) Change in Account Payables (2010 - 2026)

Nektar Therapeutics' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$934000.0 for Q1 2026.

• In Q1 2026, Change in Account Payables fell 114.57% year-over-year to -$934000.0; the TTM figure through Mar 2026 stood at -$8.0 million (down 179.17% YoY), while the FY2025 annual figure was -$625000.0, down 123.43% from the prior year.
• Change in Account Payables was -$934000.0 for Q1 2026 at Nektar Therapeutics, up from -$4.8 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $7.3 million in Q4 2022 to a low of -$8.9 million in Q1 2023.
• Historically, Change in Account Payables has averaged $78117.6 across 5 years, with a median of -$165000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables sank 552.73% in 2023, then jumped 748.79% in 2025.
• A 5-year view of Change in Account Payables shows it stood at $7.3 million in 2022, then declined by 11.57% to $6.4 million in 2023, then plunged by 42.72% to $3.7 million in 2024, then slumped by 229.86% to -$4.8 million in 2025, then jumped by 80.51% to -$934000.0 in 2026.
• The last three Change in Account Payables figures came in at -$934000.0 (Q1 2026), -$4.8 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.